1[1]Sutton GP,Blessing JA,Homesley HD,et al.Phase Ⅱ study of lfosfamide and mesna in refractory adenocarcinoma of the endometrium.Cancer,1994,73(5):1453
2[2]Burke TW,Munkaran A,Kavanag JJ,et al.Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin.Gynecol Oncol,1993,51(2):397
3[3]Sutton GP,Blessing JA,Demars LR,et al.A phase Ⅱ gynecologic oncology group trial of lfosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium.Gynecol Oncol,1996,63(1):25
4[4]Ball HG,Blessing JA,Lentz SS,et al.A phase Ⅱ trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium,Gynecol Oncol,1996,62(2):278
5[5]Pierga JY,Dieras V,Paraiso D,et al.Treatment of advenced or recurrent endometrial carcinoma with combination of etoposide,cisplatin,and 5-fluorouracil:a phase Ⅱ study.Gynecol Oncol,1996,60(1):59
6[6]Fleming BF,Fowler JM,Woggoner SE,et al.Phase Ⅰtrial of escalating dose of paclitaxel combined with fixed dose of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies:a gynecologic oncology group study.J Clin Oncol,2001,19(4):1021
7[7]Trope C,Johnsson JE,Simonsen E,et al.Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin.Am J Obstet Gynecol,1984,149(4):379
8[8]Zanotti KM,Belinson JL,Kennedy AW,et al.The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma.Gynecol Oncol,1999,74(2):272
9[9]Markman M,Kennedy A,Webster K,et al.Persistent chemosensitivity to platinum and/or paclitaxel in metastatic endometrial cancer.Gynecol Oncol,1999,73(3):422
10[10]Poplin EA,Liu PY,Delmore JE,et al.Phase Ⅱ trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma:a Southwest Oncology Group study.Gynecol Oncol,1999,74(3):432
3Kristensen G, Trope C. Endometrial cancer: the management of high-risk disease [J].Curr Oncol Rep, 2004,6(6) :471-475.
4Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006 [J], CA Cancer J Clin, 2006,56(2):106-130.
5Hannun YA. Apoptosis and the dilemma of cancer chemotherapy [J]. Blood, 1997,89(6) :1845-1853.
6Lissoni A, Gabriele A, Gorga G, et al. Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma [ J]. Ann Oncol, 1997,8 (10) :969-972.
7Fleming GF, Brunetto VL, Cella D, et al. Phase Ⅲ trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma : a Gynecologic Ontology Group Study [ J]. J Clin Oncol 2004,22( 11 ) :2159-2166.
8[1]HICKS M L, PHILLIPS J L, PARHARN G, et al. Base report on endometrial carcinoma in Africa-American women cancer [J].The National Cancer Data, 1998,83 (12) :2629-2637.
9[4]HANNUN Y A. Apoptosis and the dilemma of cancer chemotherapy[J]. Blood,1997,89(6) :1845-1853.
10[5]SUTTON G P, BLESSING J A, DEMARS L R, et al. A phase Ⅱ gynecologic oncology group trial of Ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium [J]. Gynecol Oncol, 1996,63(1):25.
